期刊文献+

小剂量5-氟尿嘧啶联合顺铂治疗低KPS评分晚期肿瘤 被引量:5

Low-dose of 5-Fluorouracil and Cisplatin for treatment of 22 low KPS cases with advanced cancer
下载PDF
导出
摘要 目的观察小剂量5-Fu联合CDDP持续滴注治疗低KPS评分晚期肿瘤的近期疗效与毒副反应。方法22例Ⅳ期肿瘤患者,KPS评分40~60分,分别予以CDDP6mg/m2,d1~5;5-Fu170mg/m·2d,d1~7;均通过化疗微量泵持续滴注,每21d为1个周期,连用2个周期以上评价疗效。结果总的有效率为18.2%;症状改善率45.5%,其中对胃肠道癌症状改善率较高为58.8%。主要毒副反应为Ⅰ~Ⅱ度胃肠道反应。结论小剂量5-氟尿嘧啶联合顺铂持续滴注治疗低KPS评分晚期恶性肿瘤安全有效。 Objective To evaluate the efficacy and toxicity of Continuous Venous Infusion of Low-dose of 5-Fluorouracil and Cisplatin on advanced low KPS cancer . Methods 22 patients with advanced cancer and low KPS (40~60)were received 5-Fu 170 mg/m^2·d,civ ,d1~7; and CDDP (6 mg/m^2·d),civ,d1~5. The treatment was given every 21 days,and 2 cycle were given to all cases. Results The overall response rate was18.2%(4/22). The rate of improving was 45.5%,and to the gastrointestinal cancer was 58.8%. The major toxic effect was (grade Ⅰ~Ⅱ) gastrointestinal side-effects. Conclusion Continuous venous Infusion of low-dose of 5-Fluorouracil and Cisplatin is an efficient and well-tolerated chemotherapeutic approach in the patients with advanced and low KPS cancer.
出处 《基层医学论坛》 2009年第22期675-676,共2页 The Medical Forum
关键词 低剂量化疗 低KPS评分 晚期恶性肿瘤 Low dose chemotherapy Lowkps Advanced cancer
  • 相关文献

参考文献1

二级参考文献10

  • 1Klement G,Huang P,Mayer B,et al.Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.Clin Cancer Res,2002;8(1):221-232.
  • 2Lau DH,Xue L,Young LJ,et al.Paclitaxel(Taxol):an inhibitor of angiogenesis in highly vascularized transgenic breast cancer.Cancer Biother Radiopharm,1999;14(1):31-36.
  • 3Inoue K,Slaton JW,Perrotte P,et al.Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.Clin Cancer Res,2000;6(12):4874-4884.
  • 4Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma.N Engl J Med,1991;324(1):1-8.
  • 5Lennernas B,Alberfesson P,Lennernas H,et al.Chemotherapy and antiangiogenesis:drug-specific,dose-related effects.Acta Oncol,2003;42(4):294-303.
  • 6Trai PA,Willner D,Bianchi AB,et al.Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.Clin Cancer Res,1999;5(11):3632-3638.
  • 7Bocci G,Francia G,Man S,et al.Thrombospondin I,a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.Proc Natl Acad Sci USA,2003;100(22):12917-12922.
  • 8Browder T,Butterfeld CE,Kvaling BM,et al.Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.Cancer Res,2000;60(7):1878-1886.
  • 9Hanahan D,Bergers G,Bergsland E.Less is more,regularly:metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.J Clin Invest,2000;105(8):1045-1047.
  • 10Lennernas B,Alberfesson P,Lennernas H,et al.Chemotherapy and antiangiogenesis:drug-specific,dose-related effects.Acta Oncol,2003;42(6):294-303.

共引文献8

同被引文献74

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部